Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals

J Jack Mellors R Raman Dhaliwal T Tom Tipton I Iain McInnes S Stefan Siebert P Pam Kearns D Dan Rea G Gordon Cook M Michelle Willicombe D David Thomas T Thushan de Silva L Lucy Wedderburn R Rossa Brugha J Jessica Bate C Carl Goodyear A Alex Richter (Clinical Immunology Services, University of Birmingham, Birmingham, United Kingdom) J John Snowden J Jack Satsangi (Centre for Human Genetics, University of Oxford, Oxford, United Kingdom) S Sean Hua Lim A Amanda Kirkham S Sarah Bowden S Sophia Magwaro A Ana Hughes A Ann Pope E Elspeth Insch V Vicky Churchill R Richard Beesley E Eilean MacDonald S Sagida Bibi C Christopher P. Conlon A Alexandra S. Deeks C Christina Dold S Susanna Dunachie J John Frater K Katie Jeffery B Barbara Kronsteiner (NDM Centre for Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom) T Teresa Lambe S Stephanie Longet A Alexander J. Mentzer (Centre for Human Genetics, University of Oxford, Oxford, United Kingdom) D Donal Skelly L Lizzie Stafford E Eleanor Barnes S Susanna J. Dunachie P Paul Klenerman (Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, United Kingdom) J Julian Hiscox M Miles Carroll

Abstract

Abstract With the continued emergence of SARS-CoV-2 variants and concerns of waning immunity, there is a need for better defined correlates of protection to aid future vaccine and therapeutic developments. Whilst neutralising antibody titres are associated with protection, these are typically determined in the absence of the complement system, which has the potential to enhance neutralisation titres and strengthen correlates with protection in vivo. Here we show that replenishment of the complement system in neutralisation assays can significantly enhance neutralisation titres, with up to an ~83-fold increase in neutralisation of the BA.1.1.529 strain using cross-reactive sera from vaccination against the ancestral strain. The magnitude of enhancement significantly varies between individuals, viral strains (wild-type/VIC01 and Omicron/BA.1), and cell lines (Vero E6 and Calu-3), and is abrogated following heat-inactivation of the complement source. Utilising ACE2 competition assays, we show that the mechanism of action is partially mediated by reducing ACE2-spike interactions. Through the addition of compstatin (a C3 inhibitor) to live virus neutralisation assays, the complement protein C3 is shown to be required for maximum efficiency. These findings further our understanding of SARS-CoV-2 immunity and neutralisation, with implications for protection against emerging variants and assessing future vaccine and therapeutic developments.

Article Details

Volume / Issue Vol. 16, Issue 1
Published March 18, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (46)

J

Jack Mellors

R

Raman Dhaliwal

T

Tom Tipton

I

Iain McInnes

S

Stefan Siebert

P

Pam Kearns

D

Dan Rea

G

Gordon Cook

M

Michelle Willicombe

D

David Thomas

T

Thushan de Silva

L

Lucy Wedderburn

R

Rossa Brugha

J

Jessica Bate

C

Carl Goodyear

A

Alex Richter

Clinical Immunology Services, University of Birmingham, Birmingham, United Kingdom

J

John Snowden

J

Jack Satsangi

Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

S

Sean Hua Lim

A

Amanda Kirkham

S

Sarah Bowden

S

Sophia Magwaro

A

Ana Hughes

A

Ann Pope

E

Elspeth Insch

V

Vicky Churchill

R

Richard Beesley

E

Eilean MacDonald

S

Sagida Bibi

C

Christopher P. Conlon

A

Alexandra S. Deeks

C

Christina Dold

S

Susanna Dunachie

J

John Frater

K

Katie Jeffery

B

Barbara Kronsteiner

NDM Centre for Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

T

Teresa Lambe

S

Stephanie Longet

A

Alexander J. Mentzer

Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

D

Donal Skelly

L

Lizzie Stafford

E

Eleanor Barnes

S

Susanna J. Dunachie

P

Paul Klenerman

Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, United Kingdom

J

Julian Hiscox

M

Miles Carroll